Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AcelRx Pharmaceuticals

Nasdaq:ACRX
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ACRX
Nasdaq
$104M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • AcelRx Pharmaceuticals has significant price volatility in the past 3 months.
ACRX Share Price and Events
7 Day Returns
11.2%
NasdaqGM:ACRX
3.1%
US Pharmaceuticals
-2.6%
US Market
1 Year Returns
-61.9%
NasdaqGM:ACRX
-3.4%
US Pharmaceuticals
-13.3%
US Market
ACRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AcelRx Pharmaceuticals (ACRX) 11.2% -9.8% -36.5% -61.9% -53.1% -68.9%
US Pharmaceuticals 3.1% -4.8% -8.7% -3.4% 8.9% 4.8%
US Market -2.6% -15.2% -22.2% -13.3% 5.7% 17.2%
1 Year Return vs Industry and Market
  • ACRX underperformed the Pharmaceuticals industry which returned -3.4% over the past year.
  • ACRX underperformed the Market in United States of America which returned -13.3% over the past year.
Price Volatility
ACRX
Industry
5yr Volatility vs Market

Value

 Is AcelRx Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AcelRx Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AcelRx Pharmaceuticals.

NasdaqGM:ACRX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ACRX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 21%) (28.69%))
0.847
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.847 * 5.44%)
6.35%

Discounted Cash Flow Calculation for NasdaqGM:ACRX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AcelRx Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:ACRX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.35%)
2020 -46.50 Analyst x2 -43.73
2021 -34.00 Analyst x2 -30.06
2022 -19.00 Analyst x2 -15.80
2023 8.00 Analyst x2 6.25
2024 25.50 Analyst x2 18.75
2025 42.59 Est @ 67.03% 29.44
2026 62.80 Est @ 47.44% 40.82
2027 83.98 Est @ 33.73% 51.34
2028 104.25 Est @ 24.13% 59.92
2029 122.41 Est @ 17.42% 66.16
Present value of next 10 years cash flows $183.00
NasdaqGM:ACRX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $122.41 × (1 + 1.74%) ÷ (6.35% – 1.74%)
$2,703.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,703.85 ÷ (1 + 6.35%)10
$1,461.40
NasdaqGM:ACRX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $183.00 + $1,461.40
$1,644.40
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,644.40 / 80.41
$20.45
NasdaqGM:ACRX Discount to Share Price
Calculation Result
Value per share (USD) From above. $20.45
Current discount Discount to share price of $1.29
= -1 x ($1.29 - $20.45) / $20.45
93.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price AcelRx Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $1.29 vs Future cash flow value of $20.45
Current Discount Checks
For AcelRx Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • AcelRx Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • AcelRx Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AcelRx Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AcelRx Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ACRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.67
NasdaqGM:ACRX Share Price ** NasdaqGM (2020-04-06) in USD $1.29
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.1x
United States of America Market PE Ratio Median Figure of 2,946 Publicly-Listed Companies 12.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AcelRx Pharmaceuticals.

NasdaqGM:ACRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ACRX Share Price ÷ EPS (both in USD)

= 1.29 ÷ -0.67

-1.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AcelRx Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • AcelRx Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AcelRx Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:ACRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
67.7%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AcelRx Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AcelRx Pharmaceuticals's assets?
Raw Data
NasdaqGM:ACRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.52
NasdaqGM:ACRX Share Price * NasdaqGM (2020-04-06) in USD $1.29
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.29x
United States of America Market PB Ratio Median Figure of 5,158 Publicly-Listed Companies 1.22x
NasdaqGM:ACRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ACRX Share Price ÷ Book Value per Share (both in USD)

= 1.29 ÷ -0.52

-2.48x

* Primary Listing of AcelRx Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AcelRx Pharmaceuticals has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.
X
Value checks
We assess AcelRx Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. AcelRx Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AcelRx Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
67.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AcelRx Pharmaceuticals expected to grow at an attractive rate?
  • AcelRx Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • AcelRx Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • AcelRx Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ACRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ACRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 67.7%
NasdaqGM:ACRX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 53.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ACRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ACRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 231 59 132 4
2023-12-31 156 30 77 4
2022-12-31 79 -19 16 5
2021-12-31 34 -37 -24 5
2020-12-31 14 -41 -43 5
2020-04-07
NasdaqGM:ACRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -51 -53
2019-09-30 2 -46 -51
2019-06-30 2 -41 -51
2019-03-31 2 -35 -49
2018-12-31 2 -29 -47
2018-09-30 2 -27 -44
2018-06-30 3 -27 -45
2018-03-31 5 -30 -48
2017-12-31 8 -30 -52
2017-09-30 14 -33 -51
2017-06-30 16 -31 -50
2017-03-31 17 -31 -48

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AcelRx Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • AcelRx Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ACRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from AcelRx Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ACRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.03 1.80 0.48 4.00
2023-12-31 0.62 1.04 0.41 4.00
2022-12-31 0.12 0.34 -0.15 5.00
2021-12-31 -0.27 -0.03 -0.45 5.00
2020-12-31 -0.49 -0.27 -0.60 5.00
2020-04-07
NasdaqGM:ACRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.67
2019-09-30 -0.67
2019-06-30 -0.71
2019-03-31 -0.75
2018-12-31 -0.81
2018-09-30 -0.83
2018-06-30 -0.90
2018-03-31 -0.98
2017-12-31 -1.10
2017-09-30 -1.12
2017-06-30 -1.10
2017-03-31 -1.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AcelRx Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess AcelRx Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AcelRx Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AcelRx Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AcelRx Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AcelRx Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AcelRx Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AcelRx Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
AcelRx Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AcelRx Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ACRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.29 -53.24 45.03
2019-09-30 2.43 -51.38 39.89
2019-06-30 2.20 -51.10 34.14
2019-03-31 2.07 -49.23 26.76
2018-12-31 2.15 -47.15 20.77
2018-09-30 2.28 -44.48 17.03
2018-06-30 3.39 -45.03 16.24
2018-03-31 5.23 -47.55 16.46
2017-12-31 8.00 -51.51 16.61
2017-09-30 13.69 -51.31 16.78
2017-06-30 15.57 -49.69 16.52
2017-03-31 17.44 -47.73 15.96
2016-12-31 17.36 -43.16 15.60
2016-09-30 12.65 -44.02 15.54
2016-06-30 24.71 -27.55 14.32
2016-03-31 22.11 -25.35 13.46
2015-12-31 19.26 -24.40 14.20
2015-09-30 17.76 -27.67 14.91
2015-06-30 7.16 -32.07 16.63
2015-03-31 5.30 -33.75 18.94
2014-12-31 5.22 -33.35 18.35
2014-09-30 32.60 -1.77 16.93
2014-06-30 28.32 -13.42 14.59
2014-03-31 28.66 -20.30 11.61
2013-12-31 29.50 -23.43 9.88
2013-09-30 3.57 -51.72 8.48
2013-06-30 3.19 -49.31 7.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AcelRx Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if AcelRx Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AcelRx Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AcelRx Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AcelRx Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AcelRx Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AcelRx Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AcelRx Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AcelRx Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of AcelRx Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • AcelRx Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AcelRx Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:ACRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -41.42 25.15 66.14
2019-09-30 -28.27 24.01 80.40
2019-06-30 -18.42 23.77 91.55
2019-03-31 -7.89 10.03 90.15
2018-12-31 4.25 11.99 105.72
2018-09-30 -37.79 13.87 63.56
2018-06-30 -48.97 15.68 50.12
2018-03-31 -46.88 17.41 51.18
2017-12-31 -36.51 19.10 60.47
2017-09-30 -30.31 22.41 67.94
2017-06-30 -31.62 22.02 62.15
2017-03-31 -19.66 21.64 72.33
2016-12-31 -5.34 21.55 80.31
2016-09-30 3.27 21.33 92.46
2016-06-30 13.50 21.35 98.80
2016-03-31 23.44 21.13 107.16
2015-12-31 33.11 20.92 113.46
2015-09-30 39.97 20.72 104.33
2015-06-30 33.39 23.13 51.20
2015-03-31 41.09 25.14 64.44
2014-12-31 46.66 24.87 75.35
2014-09-30 59.08 24.87 85.57
2014-06-30 55.55 24.64 92.35
2014-03-31 65.06 14.49 92.88
2013-12-31 73.16 14.36 103.66
2013-09-30 53.21 10.52 75.97
2013-06-30 6.04 12.39 33.87
  • AcelRx Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if AcelRx Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AcelRx Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • AcelRx Pharmaceuticals has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 17.3% each year.
X
Financial health checks
We assess AcelRx Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AcelRx Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AcelRx Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AcelRx Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of AcelRx Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AcelRx Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AcelRx Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ACRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ACRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AcelRx Pharmaceuticals has not reported any payouts.
  • Unable to verify if AcelRx Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AcelRx Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AcelRx Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of AcelRx Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess AcelRx Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AcelRx Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AcelRx Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AcelRx Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vince Angotti
COMPENSATION $1,738,845
AGE 51
TENURE AS CEO 3.1 years
CEO Bio

Mr. Vincent J. Angotti, also known as Vince, has been the Chief Executive Officer of AcelRx Pharmaceuticals, Inc. since March 6, 2017. Mr. Angotti served as the Chief Executive Officer of Xenoport, Inc. since October 1, 2015 and served as its Chief Operating Officer and Executive Vice President from June 4, 2012 to October 1, 2015. He served as Acting Chief Financial Officer of AcelRx Pharmaceuticals, Inc. from June 2, 2017 to August 16, 2017. Mr. Angotti served as the Chief Commercialization Officer and Senior Vice President of Xenoport, Inc. from May 1, 2008 to June 4, 2012. During his tenure at XenoPort, Mr. Angotti was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016.  He has over 17 years of sales and marketing experience in both large and specialty pharmaceutical businesses. Mr. Angotti served as the Senior Vice President of Sales and Marketing at Reliant Pharmaceuticals, Inc., since October 2006, where he held several positions from January 2001 to 2008. He served as Vice President of Sales and Marketing of Reliant from June 2006 to October 2006, Vice President of Sales from October 2002 to June 2006 and as its Executive Director of Sales from January 2001 to October 2002. While at Reliant, he led the expansion of a mass market and specialty sales force in the United States to promote both Lovaza, a treatment for hypertriglyceridemia and Rythmol SR. In addition, he launched co-promotion partnerships with Biovail Corporation and Amylin Pharmaceuticals, Inc. and oversaw marketing, sales, managed markets, operations and forecasting functions. Mr. Angotti served at Novartis AG (Novartis Pharmaceuticals Corp.) from 1991 to January 2001 and oversaw sales, sales management, operations and training and development. He served as Executive Director of Sales Operations of Novartis and was responsible for daily operations as well as for the mass market sales force expansions, field force productivity and effectiveness and Contract Sales Organizations. He has been a Director of AcelRx Pharmaceuticals, Inc. since March 6, 2017. He served as a Director of Xenoport, Inc. since October 1, 2015. Mr. Angotti has a Bachelor of Science degree from Cornell University in Business Management in 1990 and as an M.B.A. from Columbia University in 2000.

CEO Compensation
  • Vince's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Vince's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AcelRx Pharmaceuticals management team in years:

12.6
Average Tenure
56
Average Age
  • The average tenure for the AcelRx Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Vince Angotti

TITLE
CEO & Director
COMPENSATION
$2M
AGE
51
TENURE
3.1 yrs

Pamela Palmer

TITLE
Co-Founder
COMPENSATION
$1M
AGE
56
TENURE
14.8 yrs

Raffi Asadorian

TITLE
Chief Financial Officer
COMPENSATION
$907K
AGE
50
TENURE
2.7 yrs

Larry Hamel

TITLE
Chief Development Officer
COMPENSATION
$689K
AGE
67
TENURE
13.6 yrs

Badri Dasu

TITLE
Chief Engineering Officer
COMPENSATION
$734K
AGE
56
TENURE
12.6 yrs
Board of Directors Tenure

Average tenure and age of the AcelRx Pharmaceuticals board of directors in years:

7.9
Average Tenure
61
Average Age
  • The tenure for the AcelRx Pharmaceuticals board of directors is about average.
Board of Directors

Adrian Adams

TITLE
Chairman
COMPENSATION
$118K
AGE
68
TENURE
7.2 yrs

Vince Angotti

TITLE
CEO & Director
COMPENSATION
$2M
AGE
51
TENURE
3.1 yrs

Pamela Palmer

TITLE
Co-Founder
COMPENSATION
$1M
AGE
56
TENURE
14.8 yrs

Mark Wan

TITLE
Independent Director
COMPENSATION
$94K
AGE
53
TENURE
13.7 yrs

Mark Edwards

TITLE
Independent Director
COMPENSATION
$99K
AGE
61
TENURE
8.6 yrs

Rick Afable

TITLE
Independent Director
COMPENSATION
$91K
AGE
65
TENURE
6.3 yrs

Eugene Viscusi

TITLE
Member of Medical Advisory Board

Jonathan Schaffer

TITLE
Member of Medical Advisory Board

Mary Southam

TITLE
Member of Medical Advisory Board

William Schmidt

TITLE
Member of Medical Advisory Board
AGE
68
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Nov 19 Buy Mark Edwards Individual 12. Nov 19 12. Nov 19 25,000 $1.78 $44,575
12. Nov 19 Buy Vincent Angotti Individual 11. Nov 19 11. Nov 19 8,379 $1.79 $14,973
26. Aug 19 Buy Mark Edwards Individual 23. Aug 19 26. Aug 19 15,000 $2.20 $32,806
06. Jun 19 Buy Vincent Angotti Individual 05. Jun 19 05. Jun 19 5,000 $2.31 $11,550
X
Management checks
We assess AcelRx Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AcelRx Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Loss-Making AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Expected To Breakeven

AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX):. … AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. … The US$166.65m market-cap posted a loss in its most recent financial year of -US$51.51m and a latest trailing-twelve-month loss of -US$45.03m shrinking the gap between loss and breakeven?

Simply Wall St -

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX): Did It Outperform The Industry?

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Investors may find my commentary, albeit very high-level and brief, on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) useful as an attempt to give more color around how AcelRx Pharmaceuticals is currently performing. … ACRX is loss-making, with the most recent trailing twelve-month earnings of -US$47.55m (from 31 March 2018), which compared to last year has become

Simply Wall St -

Who Are The Largest Shareholders In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?

Insider Ownership Another important group of shareholders are company insiders. … However, a higher level of insider ownership has been linked to management executing on high-returning projects instead of expansion projects for the sake of apparent growth. … An investor should be encouraged by the ownership of these institutions who are known to be experts in increasing efficiency, improving capital structure and opting for value-accretive policy decisions.Next Steps: Institutional ownership level and composition in ACRX is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Interested In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)? Here's How It Performed Recently

In this article, I will take a look at AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … Check out our latest analysis for AcelRx Pharmaceuticals Did ACRX perform worse than its track record and industry? … NasdaqGM:ACRX Income Statement May 9th 18 We can further examine AcelRx Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Top Growth Stocks in May

Founded in 2005, and currently run by Vincent Angotti, the company size now stands at 41 people and with the stock's market cap sitting at USD $127.59M, it comes under the small-cap category. … Formed in 1994, and currently headed by CEO Keith Myers, the company now has 11,935 employees and with the stock's market cap sitting at USD $2.35B, it comes under the mid-cap stocks category. … NasdaqGM:XENT Future Profit May 6th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.

Simply Wall St -

How Do Analysts See AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Performing Over The Next Few Years?

In December 2017, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) released its latest earnings announcement, which revealed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below, I've presented key growth figures on how market analysts perceive AcelRx Pharmaceuticals's earnings growth outlook over the next couple of years and whether the future looks brighter. … See our latest analysis for AcelRx Pharmaceuticals Market analysts' prospects for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, arriving at -US$55.78M in 2019. … NasdaqGM:ACRX Future Profit Apr 10th 18 While it is helpful to understand the growth each year relative to today’s value, it may be more insightful estimating the rate at which the earnings are moving every year, on average.

Simply Wall St -

What Are Analysts Expecting From AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) In Next 12 Months?

I've plotted out each year's earnings expectations and inserted a line of best fit to calculate an annual growth rate from the slope in order to understand the overall trajectory of ACRX's earnings growth over these next few years. … NasdaqGM:ACRX Future Profit Mar 29th 18 This results in an annual growth rate of 52.43% based on the most recent earnings level of -US$51.51M to the final forecast of -US$63.52M by 2021. … Future Earnings: How does AcelRx Pharmaceuticals's growth rate compare to its peers and the wider market?

Simply Wall St -

When Will AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Turn A Profit?

AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. … In this article, I will touch on the expectations for ACRX’s growth and when analysts expect the company to become profitable. … Next Steps: There are too many aspects of ACRX to cover in one brief article, but the key fundamentals for the company can all be found in one place – ACRX’s company page on Simply Wall St.

Simply Wall St -

Does AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX) Past Performance Indicate A Weaker Future?

Today I will take a look at AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past few years, as well as how the rest of the pharmaceuticals industry performed. … Though AcelRx Pharmaceuticals's past data is helpful, it is only one aspect of my investment thesis. … I recommend you continue to research AcelRx Pharmaceuticals to get a better picture of the stock by looking at: 1.

Simply Wall St -

What Do Analysts Think About AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX) Future?

AcelRx Pharmaceuticals Inc's (NASDAQ:ACRX) announced its latest earnings update in September 2017, which confirmed company earnings became less negative compared to the previous year's level - great news for investors Below, I've laid out key growth figures on how market analysts predict AcelRx Pharmaceuticals's earnings growth outlook over the next few years and whether the future looks brighter. … View our latest analysis for AcelRx Pharmaceuticals Analysts' expectations for the coming year seems pessimistic, with earnings becoming even more negative, generating $-53.5M in 2018. … The slope of this line is the rate of earnings growth, which in this case is 5.41%.

Simply Wall St -

Company Info

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Details
Name: AcelRx Pharmaceuticals, Inc.
ACRX
Exchange: NasdaqGM
Founded: 2005
$103,731,294
80,411,856
Website: http://www.acelrx.com
Address: AcelRx Pharmaceuticals, Inc.
351 Galveston Drive,
Redwood City,
California, 94063,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ACRX Common Stock Nasdaq Global Market US USD 11. Feb 2011
DB R5X Common Stock Deutsche Boerse AG DE EUR 11. Feb 2011
Number of employees
Current staff
Staff numbers
99
AcelRx Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 04:31
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.